Weight & body composition
Retatrutide vs Mazdutide
Both activate glucagon-related pathways but retatrutide is GIP/GLP-1/glucagon tri-agonist and mazdutide is GLP-1/glucagon dual agonist; development/approval.
At a glance
Retatrutide
Mazdutide
Human evidence
Randomized Phase II obesity data show major weight reduction. A 98-participant MASLD substudy also showed large dose-dependent liver-fat reductions, including >80% mean relative reduction at the two highest studied doses by week 24.
Phase 3 GLORY trials show substantial weight loss in Chinese adults. Mazdutide received its first approval in China in June 2025 for long-term weight management and later for type 2 diabetes.
Research focus
Obesity, weight management, metabolic disease
Obesity, type 2 diabetes, metabolic liver disease, obstructive sleep apnoea
Regulatory status
Not FDA-approved as of this review; FDA states retatrutide has not been found safe and effective for any condition and cannot be used in US compounding.
First approved in China in June 2025 for chronic weight management in qualifying adults; later approved there for glycaemic control in type 2 diabetes. Not a globally authorised medicine.
Route / formulation
Evidence applies to trial-grade retatrutide, not to unverified research-market vials or pens.
Clinical evidence concerns regulated trial/authorised subcutaneous formulations. Research-market material cannot be assumed equivalent.
No direct head-to-head outcome trial identified Both activate glucagon-related pathways but retatrutide is GIP/GLP-1/glucagon tri-agonist and mazdutide is GLP-1/glucagon dual agonist; development/approval stages differ.